Keywords: AstrZeneca, Seroquel, Monotherapy, Major depressive disorder, FDA
Safety and clinical benefits of AstraZeneca’s Seroquel XR need to be demonstrated for its approval as an MDD monotherapy, says DR
Article | 28 January 2010
The recent decision by the US Food and Drug Administration to grant approval of Anglo-Swedish drug major AstraZeneca's Seroquel XR (quetiapine fumarate) for adjunctive treatment of major depressive disorder will not change Decision Resources' market projection for the indication. As previously forecast by the research and advisory firm, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
